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Pulmonary functionAbstract Pulmonary surfactant protein D (SP-D) is considered a candidate biomarker for lung
integrity and for disease progression. In the present study, we aimed to estimate the serum levels
of SP-D in patients with chronic obstructive pulmonary disease (COPD) and to assess the correla-
tion of these biomarkers with indices of COPD severity.
Subjects and methods: The study was carried out on 30 COPD male patients and 15 apparently
healthy age-matched males as control. COPD patients were divided by GOLD stages into 10
patients stage I–II (group 1), and 20 patients stage III–IV (group 2). A detailed history and clinical
examination, pulmonary function testing by spirometry, right ventricular function assessment by
conventional echocardiography and tissue Doppler imaging were done. Serum levels of total pro-
tein and albumin were determined as well as serum SP-D by enzyme-linked immunosorbent assay
in both patient and control groups was determined.
Results: The serum level of SP-D was signiﬁcantly higher in COPD patients than controls
(P< 0.001). Also, these biomarkers were signiﬁcantly higher in stages III and IV (group 2) com-
pared to stages I and II (group 2) (P< 0.01). SP-D was signiﬁcantly negatively correlated witha, Cairo
554 D.S.E. Zaky et al.serum albumin (P< 0.01) and FEV1 (P< 0.05) and not correlated with any of right ventricular
function indices measured by echocardiography.
Conclusion: SP-D is a promising biomarker for severity in stable COPD patient. The low serum
albumin could contribute to elevated serum SPD with deteriorated lung functions in stable COPD
patient.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.Introduction
Chronic obstructive pulmonary disease (COPD) is a complex
lung disease that is characterized by air ﬂow obstruction that
is not fully reversible. It is a major cause of morbidity and
mortality worldwide and is estimated to become the third lead-
ing cause of death in 2020 [1]. COPD is intimately linked to
inﬂammation, documented locally and systemically. Attention
has been increased on the level of inﬂammatory markers and
their relation to clinical and physiological measurements [2].
The relationship between serum biomarkers and clinical
expressions of COPD is limited. Pneumoproteins (proteins
synthesized predominantly in the lungs) are promising blood
biomarkers because they have high speciﬁcity for lung disease.
One of them is surfactant protein-D (SP-D), which is a macro-
molecular lipoprotein complex synthesized by type II pneumo-
cytes and Clara cells [3]. Although surfactant protein was
originally described for its essential role in reducing surface
tension at the air–liquid interface of the lung, it is recognized
also to have many other functions in innate immunity, regula-
tion of cellular clearance as well as inﬂammatory and immune
responses. Increased serum levels of SP-D have been reported
for lung diseases such as pulmonary alveolar proteinosis, cystic
ﬁbrosis, COPD, and for infectious diseases like tuberculosis
and bacterial pneumonia [4]. Lomas et al. [5] also report an
association between high serum SP-D levels and an increased
risk for COPD exacerbations. These data suggest that SP-D
levels in serum may reﬂect disease activity and SPD has there-
fore been suggested as a potential biomarker for the epithelial
integrity in COPD. SP-D translocates from the lung into the
blood, a process that could be regulated by changes in the alve-
olar-capillary permeability. For smokers and especially for
COPD patients reduced levels of SP-D were detected in bron-
choalveolar lavage ﬂuid (BAL), however, an elevated concen-
tration was detected in serum [6]. We planned in this study
to assist the relationship between serum SP-D and various
parameters of severity in COPD patients in terms of serum
protein level, pulmonary function test and right ventricular
functions by echo cardiograph, aiming to ﬁgure out the path-
ogenic role of this Pneumoprotein in COPD.Patients and methods
Study population
This study was conducted in the AL-Zahraa hospital of Al-Az-
har University, Cairo, Egypt. 30 patients with COPD are in-
cluded in the study with 15 apparently healthy individuals as
control. Written informed consent was obtained from each
participating patient and control subjects prior to the study.
COPD patients were selected from internal medicine and chestoutpatient clinic when they attended regular follow up. They
fulﬁlled the criteria for COPD (post bronchodilator FEV1/
FVC< 0.7 and >10 pack/year smoking history) [7] and were
in stable condition (no exacerbation for at least 3 months).
Exclusion criteria included myocardial infarction within the
past six months, angina, congestive heart failure, malignancy,
hepatic cirrhosis, end-stage renal disease, rheumatoid arthritis,
neurological or psychiatry illness and tuberculosis. Partici-
pants completed a medical history with especial attention to
respiratory symptoms, co-morbid conditions, and current
medications. Physical examinations including respiratory, car-
diac and other system examinations were done. Blood pressure
(BP) measurements were done by sphygmomanometer as a
mean of three times at different occasions in sitting position.
Body mass index (BMI) was calculated using the equation
BMI = weight (in kilograms) divided by the square of the
height (in meters).
Pulmonary function tests
Spirometry was carried out using Spirosift spirometry 5000
FUKUDa NENSHI. The following activities were avoided
prior to the spirometric study according to the guidelines of
American Thoracic Society (2005) [8]: (1) Smoking within at
least 1 h of testing, (2) Performing vigorous exercise within
30 min of testing, (3) Wearing clothes that substantially restrict
full chest and abdominal expansion, (4) Eating large meal
within 2 h of testing, (5) Inhaled short-acting bronchodilators,
long-acting b-agonists, and sustained-release theophyline, were
withheld for 6 h, 12 h, and 24 h, respectively. The procedures
for Spirometry include: (1) The test explained and discussed
to the patients, (2) The patient was prepared by asking the pa-
tient about the activities that should be avoided before the test,
recording the weight recorded to the nearest kilogram and
height was measured to the nearest centimeter without shoes,
(3) The doctor’s hands were washed, (4) The patient was in sit-
ting position with head slightly elevated, (5) The patient’s nose
was closed by nose clip; a mouthpiece was placed in his mouth
and was asked to close his lips around the mouthpiece, (6) The
patient was asked to inhale completely and rapidly with a
pause of <1 s at total lung capacity (TLC), and then in one
continuous sequence exhale maximally until no more air is ex-
pelled (The previous step was repeated as necessary for a min-
imum of three maneuvers). The following spirometric-indices
were recorded: Slow Vital Capacity (SVC%), Forced Vital
Capacity (FVC%), Forced Expiratory Volume in the ﬁrst sec-
ond (FEV1%), FEV1/FVC%, and Forced Expiratory Flow
(FEF 25–75%). Spirometric–indices were calculated using
the best out of three technically satisfactory trials in accor-
dance to the recommendations of the ATS, 1987 [9]. All of
COPD patients had irreversible/partially reversible obstruction
of airﬂow. COPD patients had a post-bronchodilator
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FVC% not >70%. They had an increase in FEV1 < 200 mL,
or <12% of baseline value 20 min after 2 puffs of inhaled
salbutamol (100 lg) given via a metered-dose inhaler. COPD
patients were categorized by GOLD stages into group (1) in-
cludes stage I = mild (FEV1P 80% predicted) and stage
II = moderate (50% 6 FEV1 < 80% predicted) and group
(2) includes both stage III = sever (30% 6 FEV1 < 50% pre-
dicted) and stage IV = very sever (FEV1 < 30% predicted)
[10].
Echo-Doppler study
Echo-Doppler studies were performed at rest with the patient
at steady state in the left lateral position, using Vivid-7 GE sys-
tem with tissue Doppler imaging capability using multi fre-
quency (2.5–3.5 MHz) matrix probe M3S with simultaneous
ECG physiosignal display. (A) Conventional echo-Doppler
assessment: (1) Two dimensional guided M-mode measure-
ments of RV end diastolic dimension (RVEDd) and RV end
systolic dimension (RVESd), were measured from the paraster-
nal short axis view at the level of aorta (AO)/left atrium (LA).
Right ventricular percentage fractional shortening (RV%FS)
was calculated according to Lindqvist et al. [11]:
RV%FS = {(RVEDd – RVESd)/RVEDd · 100. (2) Tricuspid
annular plane systolic excursion (TAPSE) was obtained by
measuring the level of systolic excursion of the lateral tricuspid
valve annulus from the apical four chamber view. (3) Right
ventricular percentage of fractional area change (S/D ratio)
was calculated by direct computer measurement [12], RV areas
were determined by manual tracing of the endocardial borders
in systole and diastole. (4) Pulmonary acceleration time (P acc.
T) was obtained from the pulmonary ﬂow signals from short
axis view at the level of AO/LA using pulsed wave Doppler.
(5) Right ventricular pressure (RVP) was measured in all pa-
tients from the tricuspid regurgitation (TR) jet; RVP was cal-
culated using continuous wave Doppler as peak systolic
pressure gradient (SPG) across the tricuspid valve + right at-
rial (RA) pressure. Systolic pressure gradient was calculated
by the modiﬁed Bernoulli equation [13]: SPG= 4V2 (V is
the maximum velocity of the TR jet). (6) Values of RVP were
assessed empirically in the NL group without TR ranging from
20 to 28. (B) Tissue Doppler imaging (TDI): tissue Doppler
imaging was activated to store color tissue Doppler 2D echo
loops of the apical four chamber view. Furthermore off-line
analysis of digital trace proﬁle of the pulsed wave tissue Dopp-
ler was made at tricuspid annulus of the RV free wall. The fol-
lowing measurements were obtained: (1) Peak systolic velocity
of the lateral tricuspid annulus (Lat-Sa). (2) Peak early dia-
stolic velocity of the lateral tricuspid annulus (Lat-Ea). (3)
Peak late diastolic velocity of the lateral tricuspid annulus
(Lat-Aa). (4) Ratio of early to late diastolic velocities of the
lateral tricuspid annulus (Lat Ea/Aa).
Laboratory investigations
Blood sample were obtained from all patients and immediately
centrifuged, separated into aliquots to prepare for further as-
says. Human Pulmonary SP-D was detected by ELISA immu-
noassay Kits from Cusabio Systems. Catalogue number CSB-
E11166h. The standards, samples and controls were pipettedinto wells, pre-coated with Antibody speciﬁc for SP-D and
any SP-D present is bound by the immobilized antibody. After
removing any unbound substances, a biotin-conjugated anti-
body speciﬁc for SP-D is added to the wells. After washing,
avidin conjugated Horseradish Peroxidase (HRP) is added to
the wells. Following a wash to remove any unbound avidin-en-
zyme reagent, a substrate solution is added to the wells and
color develops in proportion to the amount of SP-D bound
in the initial step. The color development is stopped and the
intensity of the color is measured.
Statistical methods
IBM SPSS statistics (V. 21.0, IBM Corp., USA, 2012) was
used for data analysis. Data were expressed as Mean ± SD
for quantitative parametric measures in addition to Median
Percentiles for quantitative non-parametric measures. The fol-
lowing tests were done: (1) Comparison between two indepen-
dent mean groups for parametric data using Student’s t test.
(2) Comparison between two independent groups for non-
parametric data using Wilcoxon Rank Sum test. (3) Ranked
Sperman correlation test to study the possible association be-
tween each of two variables among each group for non-para-
metric data. The probability of error at 0.05 was considered
signiﬁcant, while at 0.01 and 0.001 are highly signiﬁcant.
Results
The description of demographic and laboratory data of all pa-
tients (n= 30) and control individuals (n= 15) is presented in
Table 1. Results are expressed as mean ± standard deviation
or median with range as appropriate. Both patients and con-
trols are males with matched age (55.2 ± 5.1 versus
54.7 ± 3.9), and BMI (25.5 ± 4.6 versus 24.9 ± 1.44). The
median amount of cigarette consumption was 40 pack/year
in COPD patients ranging from 10 to 220 pack/year while; it
was not exceeding 12 pack/year in control individuals ranging
from 10 to 15 pack/year. The median duration of the disease in
COPD patients was 27 years ranging between 7 and 45 years.
There was also signiﬁcant decrease in total protein in patients
(7.1 ± 0.7) compared to control (7.5 ± 0.08) however, in spite
of decreased mean serum albumin in patients (3.5 ± 0.4) com-
pared to control (3.9 ± 0.3) no signiﬁcant differences were de-
tected. The mean serum level of SPD was signiﬁcantly elevated
in COPD patients (5.2 ± 3) compared to healthy control
(1.9 ± 0.2) P< 0.001 (Fig. 1).
The description of the pulmonary functions and echocardi-
ography study of the COPD patients is presented in Table 2,
and its correlation with serum SPD in Table 3. The correlation
between serum SP-D and demographic data was insigniﬁcant;
however there was negative correlation between SP-D and ser-
um albumin (Fig. 2) as well as with FEV1 (Fig. 3). Serum albu-
min is also negatively correlated to FEV1 (Table 4 and Fig. 4).
None of the echo measurements were correlated with SP-D.
In order to further characterize the relationship between in-
creased SPD and progression of COPD, we classify the pa-
tients by GOLD stages into group (1) includes 10 patients
with stages I and II as well as group (2) includes 20 patients
with stages III and IV. Demographic criteria were equally dis-
tributed between groups 1 and 2 COPD patients (Table 5).
Laboratory data show signiﬁcant decrease in serum albumin
Table 1 Description of demographic and laboratory data of
COPD patients and control individuals.
Variables Patients N= 30 Control N= 15 P-Value
Age/years 55.2 ± 5.1 54.7 ± 3.9 0.758
Body weight/kg 72.8 ± 13 73.33 ± 11.26 0.912
Height/cm 168.9 ± 9.8 171.66 ± 16.71 0.643
BMI 25.5 ± 4.6 24.9 ± 1.44 0.56
Smoking index
(pack/year)
40 (10–220) 12 (10–15) 0.00
Duration of the
disease/years
27 (7–45)
Total protein (g/dl) 7.1 ± 0.7 7.5 ± 0.08 0.003
Serum albumin (g/dl) 3.5 ± 0.4 3.9 ± 0.3 0.806
SP-D (ng/ml) 5.2 ± 3 1.9 ± 0.2 0.00
BMI = body mass index, SPD= surfactant protein-D.
±
±
Figure 1 Comparison between mean serum level of SP-D in
COPD patients and control. SPD = surfactant protein D.
Table 2 Description of the pulmonary functions and echo-
cardiography of the COPD patients.
Variables function test: Patients N= 30
Pulmonary function test (% predicted)
VC 52.1 ± 14.9
FVC 47.3 ± 15.8
FEV1 40.9 ± 16.2
FEV1_FVC 59.3 ± 11.4
FEF 26.2 ± 12.4
Echocardiography
RVEDd (cm) 2.7 ± 0.5
RVESd (cm) 1.6 ± 0.4
RV A1 21.4 ± 3.3
RV A2 11.2 ± 2.5
RV AR% 51.8 ± 7.9
PAP (mmHg) 44.6 ± 12.7
TAPSE (cm/s) 2.1 ± 0.3
Lat-Sa 10.7 ± 2.1
VC= vital capacity; FVC= forced vital capacity; FEV1=;
FEF= Forced Expiratory Volume in the ﬁrst second; LVE-
F = left ventricular ejection fraction; RVEDd= Right ventricular
end diastolic dimension; RVESd = Right ventricular end systolic
dimension; Lat-Sa: Peak systolic velocity of the lateral tricuspid
annulus.
Table 3 Correlation between SP-D and demographic charac-
teristics, laboratory investigation, pulmonary functions and
echo data of COPD patients.
Variables Serum SP-D
R P Sig
Demographic data
Age/years 0.332 0.073 NS
BMI 0.207 0.272 NS
Smoking index (pack/year) 0.013 0.945 NS
Duration of the disease (year) 0.188 0.32 NS
Laboratory data
Total protein (gm/dl) 0.204 0.28 NS
Serum albumin (gm/dl) 0.503 0.005 S
Pulmonary function test (% predicted)
VC 0.355 0.055 NS
FVC 0.353 0.056 NS
FEV1 0.372 0.043 S
FEV1_FVC 0.046 0.811 NS
FEF 0.178 0.347 NS
Echocardiography data
RVEDd (cm) 0.023 0.904 NS
RVESd (cm) 0.023 0.904 NS
RV A1 0.221 0.24 NS
RV A2 0.246 0.19 NS
RV AR% 0.188 0.319 NS
PAP (mmHg) 0.132 0.486 NS
TAPSE (cm) 0.192 0.31 NS
LTA_S (cm/s) 0.181 0.338 NS
Lat-Ea (cm/s) 0.324 0.09 NS
Lat-Aa (cm/s) 0.082 0.7 NS
Lat Ea/Aa 0.360 0.05 S
BMI = body mass index; SP-D: surfactant protein-D: VC = vital
capacity; FVC= forced vital capacity; FEV1=; FEF = Forced
Expiratory Volume in the ﬁrst second; LVEF= left ventricular
ejection fraction; RVEDd= Right ventricular end diastolic
dimension; RVESd = Right ventricular end systolic dimension;
Lat-Sa: Peak systolic velocity of the lateral tricuspid annulus; Lat-
Ea: Peak early diastolic velocity of the lateral tricuspid annulus;
Lat-Aa: late diastolic velocity of the lateral tricuspid annulus; Lat
Ea/Aa: Ratio of early to late diastolic velocities of the lateral
tricuspid annulus.
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P< 0.05. SPD serum level increased as lung functions deteri-
orate evident by highly signiﬁcant increase in SPD in group 2
(6.18 ± 3.2) compared to group 1 (3.4 ± 1.4) P< 0.05. Therewere progressive increases in serum SPD in control, group 1
and group 2 (Fig. 5). There were no signiﬁcant differences in
the pulmonary artery pressure across the spectrum of COPD
patients.
Discussion
COPD poses a major health burden worldwide, and the devel-
opment of novel therapeutics for COPD has been impeded by
lack of good surrogate markers that can track disease progres-
sion and predict clinical outcome. In the current study; we
investigated the relationships between serum SP-D levels,
and course of COPD in terms of pulmonary and cardiac func-
tions aiming to characterize SPD as lung-speciﬁc blood bio-
marker of severity in patients with stable COPD. Previous
studies in COPD patients have demonstrated increased serum
SP-D levels during an acute episode [14,15], as well as a posi-
tive correlation between the serum SP-D levels and exacerba-
Figure 2 Correlation between SPD and serum albumin in COPD patients.
Figure 3 Correlation between SPD level and FEV1 in COPD patients.
Table 4 Correlation between serum albumin and pulmonary
functions in COPD patients.
Variables Serum albumin
R P Sig
VC 0.286 0.125 NS
FVC 0.328 0.077 NS
FEV1 0.41 0.024 S
FEV1_FVC 0.047 0.807 NS
FEF 0.331 0.074 NS
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levels during an acute episode suggest that the SP-D may be
a potential systemic biomarker for COPD exacerbation. How-
ever, its role as reﬂecting the overall severity in stable COPD is
still questionable. Our patients with stable COPD showed sig-
niﬁcant increase in mean serum level of SPD compared to
healthy individuals (P< 0.001). SP-D is also increased with
deterioration of lung functions as evident by signiﬁcant in-
crease in serum SPD in patients with stages III and IV com-
pared to stages I and II COPD. These data are in line with
El-Deek SE and his colleagues [17] who demonstrated high le-
vel of SPD as well as soluble intercellular adhesion molecule-1
(sICAM-1), and high-sensitivity C-reactive protein (hs-CRP)
in patients with COPD compared to control. These data arealso consistent with Sin and his colleagues [18] who found an
increase in serum SPD in severe COPD patients at baseline
and they tracked signiﬁcant change in circulating SPD level
over a 3 month period in correlation with changes in Chronic
Respiratory Disease Questionnaire scores such that patients
who had the largest declines in serum SPD levels experienced
the largest gains in health status. The association was particu-
larly notable between circulating SPD level and the dyspnea
score. With respect to pulmonary functions our data also
revealed negative correlation between SPD and FEV1
(P< 0.05) which considered SPD as a promising biomarker
for the assessment of severity in patients with COPD. These
data were consistent with previous data [15–17] that support
a signiﬁcant negative correlation between serum SP-D and
FEV1. Since lung is the major source of SPD production,
the origin of serum SP-D is currently considered to be the lung.
With lung injury, SPD may leak out from the lung compart-
ments into the systemic circulation, causing a rise in serum
SPD. The decreased concentration of SPD in bronchoalveolar
lavage ﬂuid with simultaneous increase in its level in the serum
was observed in Winkler et al. study [19] supporting the perme-
ability hypothesis. The current study also presented new data
demonstrating that serum SPD was negatively correlated to
serum albumin in stable COPD patients. Low serum albumin
level was associated with a prolonged length of stay in the hos-
pital after acute exacerbation in COPD patients [20] as well as
serum albumin <35 g/L is considered a prognostic factor in
Table 5 Comparison between COPD patients classiﬁed according to FEV1.
Variables Group 1 (stages I and II COPD
patients) N= 10
Group 2 (stages III and IV COPD
patients) N= 20
P-
Value
Age/years 54.1 ± 6.1 55.7 ± 4.6 0.477
BMI 24.87 ± 3.7 25.8 ± 5 0.587
Smoking index (pack/
year)
40 (20–180) 40 (10–220) 0.755
Duration of the disease
(years)
25 (7–35) 30 (14–45) 0.117
Serum protein (mg/dl) 7.16 ± 0.9 7 ± 0.6 0.656
Serum albumin (mg/dl) 4.17 ± 0.4 3.8 ± 0.4 0.045
SPD (ng/ml) 3.4 ± 1.4 6.18 ± 3.2 0.005
RVEDd (cm) 3.9 ± 0.9 3.7 ± 0.64 0.65
RVESd (cm) 2.2 ± 0.76 2.0 ± 0.5 0.49
RV A1 22 ± 2.9 21 ± 3.5 0.411
RV A2 12 ± 3.2 10.8 ± 2 0.39
RV AR% 53.4 ± 8.7 50.9 ± 7.5 0.458
TAPSE (cm) 2.04 ± 0.3 2.1 ± 0.2 0.439
PAP (mmHg) 45.6 ± 14 44.1 ± 12.2 0.982
Lat-Sa (cm/s) 9.9 ± 1.8 10.76 ± 1.8 0.31
Lat-Ea (cm/s) 7.1 ± 2.5 6.95 ± 1.8 0.75
Lat-Aa (cm/s) 12.6 ± 2.1 11.9 ± 2.0 0.37
Lat Ea/Aa 0.56 ± 0.17 0.59 ± 0.17 0.74
BMI = body mass index; SPD= surfactant protein D; PAP; Pulmonary artery pressure.
Figure 4 Correlation between serum albumin and FEV1 in COPD patients.
Figure 5 Comparison between mean level of SPD in control and
groups 1 and 2 COPD patients.
558 D.S.E. Zaky et al.acute hypercapnic respiratory failure with respiratory acidosis
due to COPD [21]. Additionally, Go¨rek Dilektasli and his col-
leagues study [22] showed that low serum protein levels can af-
fect the diffusing capacity of lungs in COPD patients as well asthe serum albumin is correlated signiﬁcantly to pulmonary
function. Our data augment the permeability hypothesis and
provide a new possible mechanism for it through increased
lung diffusability with decreased serum albumin. Low serum
albumin may be the contributing factor of transfer of SP-D
from lung compartment to the systemic circulation. We also
investigated the relationship between the raised SP-D and right
ventricular functions as consequences of lung injury and as a
determinant of vascular permeability in the lung. Our data
revealed no signiﬁcant correlation between circulating SPD
and right ventricular end systolic or diastolic parameters or
pulmonary artery pressure. The sample size of this study was
small to establish a deﬁnitive conclusion; however, further
study is necessary to evaluate the pathogenic role of circulating
SP-D and to investigate its relation with cardiac parameters. In
summary our data revealed increased circulating SPD as pul-
monary function deteriorates. Circulating SPD is negatively
correlated to serum albumin, FEV1 and has no correlation
Circulating surfactant protein-D as a biomarker of severity 559with any of right ventricular cardiac parameters. Conclusion:
SPD is a promising biomarker for severity in stable COPD
patient. The low serum albumin could contribute to elevated
serum SPD with deteriorated lung functions in stable COPD
patient.
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